Drugs Made In America Acquisition II Corp. DMII
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 112.20K | 102.00K | 1.05M | 155.50K | 38.10K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 112.20K | 102.00K | 1.05M | 155.50K | 38.10K |
| Operating Income | -112.20K | -102.00K | -1.05M | -155.50K | -38.10K |
| Income Before Tax | 4.40M | 4.34M | 4.33M | -46.20K | -38.10K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 4.40M | 4.34M | 4.33M | -46.20K | -38.10K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.40M | 4.34M | 4.33M | -46.20K | -38.10K |
| EBIT | -112.20K | -102.00K | -1.05M | -155.50K | -38.10K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.07 | 0.07 | 0.07 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.04 | 0.04 | 0.04 | 0.00 | 0.00 |
| EPS Diluted | 0.07 | 0.07 | 0.07 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.04 | 0.04 | 0.04 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 63.70M | 63.70M | 63.70M | 65.58M | 12.50M |
| Average Diluted Shares Outstanding | 63.70M | 63.70M | 63.70M | 65.58M | 12.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |